FISH OIL AND ASPIRIN IN VASCULAR ACCESS OUTCOMES IN RENAL DISEASE TRIAL (FAVOURED TRIAL). One more negative study in CKD….
Thrombosis and maturation failure remain high in hemodialysis vascular access. Aspirin has been shown to confer protection through anti-inflammatory and anti-platelet effects and fish oil through inhibition of smooth muscle cell proliferation, increased flow mediated dilation and overall decreased endothelial susceptibility to injury. The FAVOURED was presented on Nov 7, 2015 at the late-breaking clinical trial session. It is the first randomized controlled trial to assess whether fish oil and aspirin can reduce de novo AVF access failure at 12 months. Four grams of fish oil or placebo were given for 12 weeks to 567 patients and a subgroup of patients were assigned to aspirin 100 mg or placebo. There was an overall rate of 47% AVF failure and aspirin or fish oil did not change the outcomes. Authors conclude that neither fish oil or aspirin can be recommended for primary AVF failure. This study probably reflects the complex etiology of access dysfunction in dialysis patients and forces the nephrology community to think about multidisciplinary therapies to treat this relevant problem.
Post by Dr. Magdalena Madero, AJKD Blog Contributor.